Supernus Pharmaceuticals Seeks Nasdaq Delisting After Merger Completion
Supernus Pharmaceuticals seeks to delist from Nasdaq following completion of a merger.
Related stories
Meta plans potential bond sale to raise at least 200 hundred million dollars
Meta is planning a potential cross-border bond issue to raise at least 200 hundred million dollars, according to Bloomberg, Reuters reports.
M impact | EQUITY | Nov 02, 2026, 07:19 PM UTC
Lumentum shares fall more than 17%
Lumentum shares are down more than 17%, with Marvell weakness eroding the value of the all-stock takeover.
M impact | EQUITY | Nov 02, 2026, 07:19 PM UTC
報道：メタ、債券発行で少なくとも200億ドル調達を目指す
M impact | EQUITY | Nov 02, 2026, 07:19 PM UTC
S&P 500 Rises as Apple and Palantir Earnings Near
The S&P 500 rose; Apple and Palantir are set to report results.
M impact | EQUITY | Nov 02, 2026, 07:19 PM UTC
US Q3 Profit Growth Remains Strong but Is No Longer Accelerating
M impact | EQUITY | Nov 02, 2026, 07:18 PM UTC
Golden Goliath Acquires 40% Stake in Egypt’s Um Garayat Gold Blocks B and D
M impact | EQUITY | Nov 02, 2026, 07:15 PM UTC